Home

 
Latest news
 
Latest news

 
  • The next ENVI Committee meeting will take place on 29-30.05.2013 in Brussels, in building Jozsef Antall (JAN) 4Q2
 
  • The next workshop  organised by Policy Department A on Patient safety will take place on 30.05.2013 between 15.15-18.00 in Brussels, in building Altiero Spinelli(ASP) A1E-2 .
 
  • The latest studies from Policy Department A are now available:  
          from  their Utilization (Nagoya Protocol)"
     
  • The latest studies from the Impact Assessment Unit (Dir G) are now available:
             
 

   
 
Highlights
 
Clinical trials, food for infants, exchange of views with Commissioner Hedegaard

On 29-30 May, ENVI will adopt a report on clinical trials (Willmott, S&D, UK) focusing on patient safety and transparency of trial results. Another report on the composition and labelling of food for infants and for special medical purposes (Ries, ALDE, BE) will also be voted. Moreover, Members will discuss climate issues with Commissioner Hedegaard.

   
Science and Technology Options Assessment - Annual Report 2012

ITRE - AGRI - ENVI - IMCO - EMPL - TRAN (STOA): Parliament's unit for Science and Technology Options Assessment (STOA) mainly assesses the impact of introducing new technologies and identifies the best possible options for action, from a technological point of view. In 2012, STOA focused on eco-efficient transport, sustainable management of natural resources, security of the Internet, e-Government, cloud computing and social networks.

 
Further information
 
Delegation to the European Centre for Disease Prevention and Control, Stockholm

The biannual ENVI Committee delegation to ECDC, Stockholm took place on 2-3 May  to meet the executive director, Dr Sprenger and his  management team to discuss important topics such as:
-Monitoring, assessing and communicating health threats
-The Strategic Multi-Annual Programme 2014-2020
-Ensuring the excellence and independence of ECDC’s scientific advice
-Organisational performance and budget management issues
Delegation members are: Mikolasik (EPP, SK), Taylor (ALDE, UK), Rossi (EFD, IT).

 
Further information
 
Light commercial vehicles, ILUC, Environmental Impact Assessment, Commissioner Borg

During their 6-7 May meeting ENVI members adopted a draft report to define the modalities for reaching the 2020 target to reduce CO2 emissions from new light commercial vehicles. (Krahmer, ALDE, DE) Members held extensive exchange of views on draft reports on Indirect Land Use Change (Lepage, ALDE, FR) and on Environmental Impact Assessment (Zanoni, ALDE, IT). An exchange of views with Commissioner Borg in the frame of the structured dialogue also took place.

   
 
Latest press releases
See all  
ENVI 07-05-2013 - 17:27  

To reduce the CO2 emissions of new light commercial vehicles sold in the EU to 147g/km by 2020, from 203g today, innovation should be encouraged by giving "super-credit" weightings to each maker's cleaner vehicles. Longer-term CO2 reduction targets should also be set, and environmental performance testing methods should be made more realistic, said the Environment Committee on Tuesday. The top speed of vans should be electronically limited to 120km/h, it added.

ENVI 24-04-2013 - 16:12  

To reduce the CO2 emissions of new cars sold in the EU to 95g/km by 2020, from 130g today, clean-car innovation should be encouraged by giving "super-credit" weightings to each maker's cleaner cars and setting more ambitious longer-term reduction targets, said the Environment Committee on Wednesday. Environmental performance testing methods should also be made more realistic, as a matter of urgency, it added.

Powers and responsibilities
 
Committee responsible for:
1.    environmental policy and environmental protection measures, in particular concerning:
(a)    air, soil and water pollution, waste management and recycling, dangerous substances and preparations, noise levels, climate change, protection of biodiversity,
(b)    sustainable development,
(c)    international and regional measures and agreements aimed at protecting the environment,
(d)    restoration of environmental damage,
(e)    civil protection,
(f)    the European Environment Agency,
(g)    the European Chemicals Agency;
 
2.    public health, in particular:
(a)    programmes and specific actions in the field of public health,
(b)    pharmaceutical and cosmetic products,
(c)    health aspects of bioterrorism,
(d)    the European Medicines Agency and the European Centre for Disease Prevention and Control;
 
3.    food safety issues, in particular:
(a)    the labelling and safety of foodstuffs,
(b)    veterinary legislation concerning protection against risks to human health; public health checks on foodstuffs and food production systems,
(c)    the European Food Safety Authority and the European Food and Veterinary Office.
 
Today's broadcasts
 
No broadcast today  
Multimedia Library
 
Chairman's welcome
 
 

Welcome to the ENVI Committee website.
 
Counting 69 members, our Committee is the largest legislative committee in the European Parliament. We are working to see the many concerns of citizens all over Europe reflected in environmental, health and food safety legislation. The European Parliament has gained co-legislative powers in the vast majority of issues discussed in ENVI, making it one of the most influential committees.
 
Our work in the field of environmental policy comprises issues ranging from the regulation of toxic chemicals to the preservation of Europe's biodiversity. The Committee also works towards promoting a resource-efficient and sustainable Europe. The fight against climate change is at the heart of our Committee's work.
 
Recent food scandals in Member States have highlighted the need for better food safety. We critically look into legislation concerning the regulation of foodstuffs. Better information for consumers, e.g. through clearer and unambiguous labelling of products is a main concern of the ENVI Committee.
 
In the field of Public Health, ENVI strives to propose European solutions to health-related problems. Recent examples of our work comprise the safety of pharmaceutical and cosmetic products, the fight against counterfeit medicinal products and the defence of patient's rights. 
 
We hope that this website will give you a better picture of our work and we invite you to comment on any issue which is of interest to you.
 
Matthias Groote